n"May 10 (Reuters) - Abbott Laboratories said its drug, Humira, to treat ulcerative colitis, a form of inflammatory bowel disease, met the main goal of a late-stage trial. In the eighth week, 16.5 percent...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to UPDATE 1-Abbott bowel drug meets late-stage trial goal
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
account